{"id":12794,"date":"2022-02-03T07:00:29","date_gmt":"2022-02-03T06:00:29","guid":{"rendered":"https:\/\/www.sequanamedical.com\/?p=12794"},"modified":"2022-06-30T18:09:41","modified_gmt":"2022-06-30T16:09:41","slug":"sequana-medical-presenteert-op-btig-medtech-digital-health-life-science-diagnostic-tools-conference","status":"publish","type":"post","link":"https:\/\/www.sequanamedical.com\/nl\/persberichten\/sequana-medical-presenteert-op-btig-medtech-digital-health-life-science-diagnostic-tools-conference\/","title":{"rendered":"Sequana Medical presenteert op BTIG MedTech, Digital Health, Life Science &#038; Diagnostic Tools Conference"},"content":{"rendered":"<p><strong>Gent, Belgi\u00eb \u2013 3 februari 2022 <\/strong>\u2013<strong> Sequana Medical NV (<\/strong><strong>Euronext Brussels: SEQUA, de &#8220;Vennootschap&#8221; of &#8220;Sequana Medical&#8221;<\/strong>), een vernieuwer in de behandeling van diuretica-resistente vochtoverbelasting in leveraandoeningen, maligne ascites en hartfalen, kondigt vandaag aan dat Ian Crosbie, Chief Executive Officer, een presentatie zal geven tijdens <em>BTIG&#8217;s Medtech, Digital Health, Life Science and Diagnostic Tools Conference<\/em>, die virtueel plaatsvindt van 15 tot 17 februari 2022.<\/p>\n<p><strong>Bedrijfspresentatie<\/strong><\/p>\n<ul>\n<li>Woensdag, 16 februari 2022 om 14u00 Belgische tijd<\/li>\n<li>De slides van de presentatie zullen kort na het event beschikbaar zijn op de <a href=\"\/?page_id=5536\">Investors website<\/a> van Sequana Medical<\/li>\n<\/ul>\n<p>&nbsp;<\/p>\n<p>Sequana Medical zal internationale investeerders ontmoeten in virtuele 1-op-1 en kleine groepsbijeenkomsten.<\/p>\n<p>De door BTIG georganiseerde events zijn uitsluitend bedoeld voor potenti\u00eble en bestaande BTIG-klanten. Om het live-event te beluisteren, gelieve contact op te nemen met uw BTIG-vertegenwoordiger.<\/p>\n<p><strong>\u00a0<\/strong><\/p>\n<p><strong>Voor meer informatie, gelieve contact op te nemen met: <\/strong><\/p>\n<p><strong>Sequana Medical<\/strong><\/p>\n<p>Lies Vanneste<\/p>\n<p>Director Investor Relations<\/p>\n<p>Tel: +32 498 05 35 79<\/p>\n<p>Email: <a href=\"mailto:IR@sequanamedical.com\">IR@sequanamedical.com<\/a><\/p>\n<p><strong>\u00a0<\/strong><\/p>\n<p><strong>LifeSci Advisors<\/strong><\/p>\n<p>Guillaume van Renterghem<\/p>\n<p>Tel: +41 76 735 01 31<\/p>\n<p>Email: <a href=\"mailto:chris@lifesciadvisors.com\">gvanrenterghem@lifesciadvisors.com<\/a><\/p>\n<p><strong>\u00a0<\/strong><\/p>\n<p><strong>Over Sequana Medical<\/strong><\/p>\n<p>Sequana Medical is een onderneming in medische toestellen die zich in de commerci\u00eble fase bevindt en haar gepatenteerde <strong>alfa<\/strong>pump\u00ae en DSR\u00ae (<em>Direct Sodium Removal<\/em> of directe natriumverwijdering) technologie\u00ebn gebruikt om innovatieve behandelingen te onwikkelen voor vochtoverbelasting bij leveraandoeningen, maligne ascites en hartfalen wanneer diuretica niet langer effectief zijn. Vochtoverbelasting is een veelvoorkomende complicatie van veel grote ziekten \u2013 waaronder gevorderde leverziekte veroorzaakt door NASH (niet-alcoholische steatohepatitis)-gerelateerde cirrose en hartfalen \u2013 waarbij resistentie tegen diuretica wijdverspreid is. De Amerikaanse markt voor de <strong>alfa<\/strong>pump als gevolg van NASH-gerelateerde cirrose zal naar verwachting de komende 10-20 jaar meer dan \u20ac3 miljard per jaar bedragen. De markt in hartfalen voor DSR en <strong>alfa<\/strong>pump DSR\u00ae wordt geschat op meer dan \u20ac5 miljard per jaar tegen 2026 in de VS en EU5.<\/p>\n<p>De <strong>alfa<\/strong>pump is Sequana Medical&#8217;s uniek, volledig ge\u00efmplanteerd draadloos systeem dat automatisch vocht vanuit de buik in de blaas pompt, waar het op natuurlijke wijze wordt verwijderd via urinering. DSR is de gepatenteerde aanpak van Sequana Medical voor het behandelen van natrium- en vochtoverbelasting door middel van een natriumvrij infusate dat in de buikholte wordt toegediend.<\/p>\n<p>In de VS, de belangrijkste groeimarkt van de Vennootschap, heeft de FDA de <strong>alfa<\/strong>pump een <em>breakthrough device<\/em> status verleend voor terugkerende en refractaire ascites als gevolg van levercirrose. Tussentijdse resultaten van de lopende Noord-Amerikaanse pivotale studie (POSEIDON) toonden positieve resultaten voor alle primaire eindpunten en een snelle en aanhoudende klinisch belangrijke verbetering in levenskwaliteit. Alle pati\u00ebnten werden opgenomen in de studie en de rapportering van het primaire eindpunt is gepland voor Q4 2022. Deze studie is bedoeld om een toekomstige marketingapplicatie van de <strong>alfa<\/strong>pump in de VS en Canada te ondersteunen. In Europa is de <strong>alfa<\/strong>pump CE-gemarkeerd voor het behandelen van refractaire ascites als gevolg van levercirrose en maligne ascites en is opgenomen in belangrijke klinische praktijkrichtlijnen. Tot nu toe zijn meer dan 900 <strong>alfa<\/strong>pump toestellen ge\u00efmplanteerd.<\/p>\n<p>Sequana Medical heeft haar bewezen <strong>alfa<\/strong>pump en gepatenteerde DSR-therapie gecombineerd en ontwikkelt de <strong>alfa<\/strong>pump DSR, een baanbrekende aanpak voor vochtoverbelasting als gevolg van hartfalen. RED DESERT toonde aan dat herhaalde DSR-therapie bij pati\u00ebnten met hartfalen die resistent zijn tegen diuretica, niet alleen de vocht- en natriumbalans van deze pati\u00ebnten kan beheren, maar ook hun cardio-renale status verbetert en hun diuretische respons gedurende maanden na de behandeling herstelt. Tussentijdse resultaten van de lopende SAHARA DESERT studie van <strong>alfa<\/strong>pump DSR bij pati\u00ebnten met gedecompenseerd hartfalen toonden een veilige, effectieve en snelle eliminatie van aanhoudende congestie en herstel van euvolemie, samen met een aanzienlijk voordeel voor de cardio-renale status en een drastische verbetering in diuretische respons. Rapportering van de topline data is gepland voor H2 2022.<\/p>\n<p>De hoofdzetel van Sequana Medical is gevestigd in Gent, Belgi\u00eb. Meer informatie is beschikbaar op de website <a href=\"https:\/\/www.sequanamedical.com\">www.sequanamedical.com<\/a>.<\/p>\n<p>&nbsp;<\/p>\n<p><strong><em>Belangrijke Regulatoire Disclaimers<\/em><\/strong><\/p>\n<p><em>Het\u00a0<strong>alfa<\/strong>pump\u00ae systeem is momenteel niet goedgekeurd in de Verenigde Staten of Canada. In de Verenigde Staten en Canada wordt het\u00a0<strong>alfa<\/strong>pump systeem momenteel klinisch onderzocht (POSEIDON-studie) en wordt het bestudeerd bij volwassen pati\u00ebnten met refractaire of terugkerende ascites als gevolg van cirrose. Voor meer informatie over de POSEIDON klinische studie zie\u00a0<\/em><a href=\"http:\/\/www.poseidonstudy.com\/\"><em>www.poseidonstudy.com<\/em><\/a><em>. De DSR\u00ae therapie is nog in ontwikkeling en er dient te worden opgemerkt dat eventuele verklaringen met betrekking tot veiligheid en effici\u00ebntie voortkomen uit lopende preklinische en klinische onderzoeken die nog moeten worden afgerond. De DSR therapie is momenteel niet goedgekeurd voor klinisch onderzoek in de Verenigde Staten of Canada. Er is geen verband tussen de DSR therapie en de lopende onderzoeken met het\u00a0<strong>alfa<\/strong>pump systeem in Europa, de <\/em><em>Verenigde Staten of Canada.<\/em><\/p>\n<p><strong><em>Note: alfa<\/em><\/strong><em>pump\u00ae\u00a0is een geregistreerd handelsmerk. DSR\u00ae en <strong>alfa<\/strong>pump DSR\u00ae zijn geregistreerde handelsmerken in de Benelux, China, de EU, het Verenigd Koninkrijk en Hong Kong.<\/em><\/p>\n<p>&nbsp;<\/p>\n<p><strong><em>Download het <a href=\"https:\/\/www.sequanamedical.com\/wp-content\/uploads\/2022\/02\/Press-Release_3-Feb-2022_BTIG-Presentation_Dutch_vF.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">persbericht<\/a>\u00a0\u00a0\u00a0<\/em>\u00a0<\/strong><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Gent, Belgi\u00eb \u2013 3 februari 2022 \u2013 Sequana Medical NV (Euronext Brussels: SEQUA, de &#8220;Vennootschap&#8221; of &#8220;Sequana Medical&#8221;), een vernieuwer in de behandeling van diuretica-resistente vochtoverbelasting in leveraandoeningen, maligne ascites en hartfalen, kondigt vandaag aan dat Ian Crosbie, Chief Executive Officer, een presentatie zal geven tijdens BTIG&#8217;s Medtech, Digital Health, Life Science and Diagnostic Tools [&hellip;]<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[74],"tags":[94],"class_list":["post-12794","post","type-post","status-publish","format-standard","hentry","category-persberichten","tag-niet-gereglementeerd"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Sequana Medical presenteert op BTIG MedTech, Digital Health, Life Science &amp; Diagnostic Tools Conference - Sequana Medical<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.sequanamedical.com\/nl\/persberichten\/sequana-medical-presenteert-op-btig-medtech-digital-health-life-science-diagnostic-tools-conference\/\" \/>\n<meta property=\"og:locale\" content=\"nl_NL\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Sequana Medical presenteert op BTIG MedTech, Digital Health, Life Science &amp; Diagnostic Tools Conference - Sequana Medical\" \/>\n<meta property=\"og:description\" content=\"Gent, Belgi\u00eb \u2013 3 februari 2022 \u2013 Sequana Medical NV (Euronext Brussels: SEQUA, de &#8220;Vennootschap&#8221; of &#8220;Sequana Medical&#8221;), een vernieuwer in de behandeling van diuretica-resistente vochtoverbelasting in leveraandoeningen, maligne ascites en hartfalen, kondigt vandaag aan dat Ian Crosbie, Chief Executive Officer, een presentatie zal geven tijdens BTIG&#8217;s Medtech, Digital Health, Life Science and Diagnostic Tools [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.sequanamedical.com\/nl\/persberichten\/sequana-medical-presenteert-op-btig-medtech-digital-health-life-science-diagnostic-tools-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Sequana Medical\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/alfapump\" \/>\n<meta property=\"article:published_time\" content=\"2022-02-03T06:00:29+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2022-06-30T16:09:41+00:00\" \/>\n<meta name=\"author\" content=\"Lies Vanneste\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@SequanaMed\" \/>\n<meta name=\"twitter:site\" content=\"@SequanaMed\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.sequanamedical.com\\\/nl\\\/persberichten\\\/sequana-medical-presenteert-op-btig-medtech-digital-health-life-science-diagnostic-tools-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.sequanamedical.com\\\/nl\\\/persberichten\\\/sequana-medical-presenteert-op-btig-medtech-digital-health-life-science-diagnostic-tools-conference\\\/\"},\"author\":{\"name\":\"Lies Vanneste\",\"@id\":\"https:\\\/\\\/www.sequanamedical.com\\\/#\\\/schema\\\/person\\\/d19e52ba140d6e8fc2907b3b460e8ac3\"},\"headline\":\"Sequana Medical presenteert op BTIG MedTech, Digital Health, Life Science &#038; Diagnostic Tools Conference\",\"datePublished\":\"2022-02-03T06:00:29+00:00\",\"dateModified\":\"2022-06-30T16:09:41+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.sequanamedical.com\\\/nl\\\/persberichten\\\/sequana-medical-presenteert-op-btig-medtech-digital-health-life-science-diagnostic-tools-conference\\\/\"},\"wordCount\":790,\"publisher\":{\"@id\":\"https:\\\/\\\/www.sequanamedical.com\\\/#organization\"},\"keywords\":[\"Niet-gereglementeerd\"],\"articleSection\":[\"Persberichten\"],\"inLanguage\":\"nl-NL\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.sequanamedical.com\\\/nl\\\/persberichten\\\/sequana-medical-presenteert-op-btig-medtech-digital-health-life-science-diagnostic-tools-conference\\\/\",\"url\":\"https:\\\/\\\/www.sequanamedical.com\\\/nl\\\/persberichten\\\/sequana-medical-presenteert-op-btig-medtech-digital-health-life-science-diagnostic-tools-conference\\\/\",\"name\":\"Sequana Medical presenteert op BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference - Sequana Medical\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.sequanamedical.com\\\/#website\"},\"datePublished\":\"2022-02-03T06:00:29+00:00\",\"dateModified\":\"2022-06-30T16:09:41+00:00\",\"inLanguage\":\"nl-NL\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.sequanamedical.com\\\/nl\\\/persberichten\\\/sequana-medical-presenteert-op-btig-medtech-digital-health-life-science-diagnostic-tools-conference\\\/\"]}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.sequanamedical.com\\\/#website\",\"url\":\"https:\\\/\\\/www.sequanamedical.com\\\/\",\"name\":\"Sequana Medical\",\"description\":\"Pioneer in the treatment of fluid overload\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.sequanamedical.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.sequanamedical.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"nl-NL\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.sequanamedical.com\\\/#organization\",\"name\":\"Sequana Medical NV\",\"url\":\"https:\\\/\\\/www.sequanamedical.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"nl-NL\",\"@id\":\"https:\\\/\\\/www.sequanamedical.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.sequanamedical.com\\\/wp-content\\\/uploads\\\/2017\\\/09\\\/Sequana-medical_logo.png\",\"contentUrl\":\"https:\\\/\\\/www.sequanamedical.com\\\/wp-content\\\/uploads\\\/2017\\\/09\\\/Sequana-medical_logo.png\",\"width\":396,\"height\":70,\"caption\":\"Sequana Medical NV\"},\"image\":{\"@id\":\"https:\\\/\\\/www.sequanamedical.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/alfapump\",\"https:\\\/\\\/x.com\\\/SequanaMed\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/sequana-medical\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.sequanamedical.com\\\/#\\\/schema\\\/person\\\/d19e52ba140d6e8fc2907b3b460e8ac3\",\"name\":\"Lies Vanneste\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"nl-NL\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/6f62aa1d55dc8a8289dd18faa628d22e5c34f8d569432403cd0bee21b4875095?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/6f62aa1d55dc8a8289dd18faa628d22e5c34f8d569432403cd0bee21b4875095?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/6f62aa1d55dc8a8289dd18faa628d22e5c34f8d569432403cd0bee21b4875095?s=96&d=mm&r=g\",\"caption\":\"Lies Vanneste\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Sequana Medical presenteert op BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference - Sequana Medical","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.sequanamedical.com\/nl\/persberichten\/sequana-medical-presenteert-op-btig-medtech-digital-health-life-science-diagnostic-tools-conference\/","og_locale":"nl_NL","og_type":"article","og_title":"Sequana Medical presenteert op BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference - Sequana Medical","og_description":"Gent, Belgi\u00eb \u2013 3 februari 2022 \u2013 Sequana Medical NV (Euronext Brussels: SEQUA, de &#8220;Vennootschap&#8221; of &#8220;Sequana Medical&#8221;), een vernieuwer in de behandeling van diuretica-resistente vochtoverbelasting in leveraandoeningen, maligne ascites en hartfalen, kondigt vandaag aan dat Ian Crosbie, Chief Executive Officer, een presentatie zal geven tijdens BTIG&#8217;s Medtech, Digital Health, Life Science and Diagnostic Tools [&hellip;]","og_url":"https:\/\/www.sequanamedical.com\/nl\/persberichten\/sequana-medical-presenteert-op-btig-medtech-digital-health-life-science-diagnostic-tools-conference\/","og_site_name":"Sequana Medical","article_publisher":"https:\/\/www.facebook.com\/alfapump","article_published_time":"2022-02-03T06:00:29+00:00","article_modified_time":"2022-06-30T16:09:41+00:00","author":"Lies Vanneste","twitter_card":"summary_large_image","twitter_creator":"@SequanaMed","twitter_site":"@SequanaMed","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.sequanamedical.com\/nl\/persberichten\/sequana-medical-presenteert-op-btig-medtech-digital-health-life-science-diagnostic-tools-conference\/#article","isPartOf":{"@id":"https:\/\/www.sequanamedical.com\/nl\/persberichten\/sequana-medical-presenteert-op-btig-medtech-digital-health-life-science-diagnostic-tools-conference\/"},"author":{"name":"Lies Vanneste","@id":"https:\/\/www.sequanamedical.com\/#\/schema\/person\/d19e52ba140d6e8fc2907b3b460e8ac3"},"headline":"Sequana Medical presenteert op BTIG MedTech, Digital Health, Life Science &#038; Diagnostic Tools Conference","datePublished":"2022-02-03T06:00:29+00:00","dateModified":"2022-06-30T16:09:41+00:00","mainEntityOfPage":{"@id":"https:\/\/www.sequanamedical.com\/nl\/persberichten\/sequana-medical-presenteert-op-btig-medtech-digital-health-life-science-diagnostic-tools-conference\/"},"wordCount":790,"publisher":{"@id":"https:\/\/www.sequanamedical.com\/#organization"},"keywords":["Niet-gereglementeerd"],"articleSection":["Persberichten"],"inLanguage":"nl-NL"},{"@type":"WebPage","@id":"https:\/\/www.sequanamedical.com\/nl\/persberichten\/sequana-medical-presenteert-op-btig-medtech-digital-health-life-science-diagnostic-tools-conference\/","url":"https:\/\/www.sequanamedical.com\/nl\/persberichten\/sequana-medical-presenteert-op-btig-medtech-digital-health-life-science-diagnostic-tools-conference\/","name":"Sequana Medical presenteert op BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference - Sequana Medical","isPartOf":{"@id":"https:\/\/www.sequanamedical.com\/#website"},"datePublished":"2022-02-03T06:00:29+00:00","dateModified":"2022-06-30T16:09:41+00:00","inLanguage":"nl-NL","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.sequanamedical.com\/nl\/persberichten\/sequana-medical-presenteert-op-btig-medtech-digital-health-life-science-diagnostic-tools-conference\/"]}]},{"@type":"WebSite","@id":"https:\/\/www.sequanamedical.com\/#website","url":"https:\/\/www.sequanamedical.com\/","name":"Sequana Medical","description":"Pioneer in the treatment of fluid overload","publisher":{"@id":"https:\/\/www.sequanamedical.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.sequanamedical.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"nl-NL"},{"@type":"Organization","@id":"https:\/\/www.sequanamedical.com\/#organization","name":"Sequana Medical NV","url":"https:\/\/www.sequanamedical.com\/","logo":{"@type":"ImageObject","inLanguage":"nl-NL","@id":"https:\/\/www.sequanamedical.com\/#\/schema\/logo\/image\/","url":"https:\/\/www.sequanamedical.com\/wp-content\/uploads\/2017\/09\/Sequana-medical_logo.png","contentUrl":"https:\/\/www.sequanamedical.com\/wp-content\/uploads\/2017\/09\/Sequana-medical_logo.png","width":396,"height":70,"caption":"Sequana Medical NV"},"image":{"@id":"https:\/\/www.sequanamedical.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/alfapump","https:\/\/x.com\/SequanaMed","https:\/\/www.linkedin.com\/company\/sequana-medical"]},{"@type":"Person","@id":"https:\/\/www.sequanamedical.com\/#\/schema\/person\/d19e52ba140d6e8fc2907b3b460e8ac3","name":"Lies Vanneste","image":{"@type":"ImageObject","inLanguage":"nl-NL","@id":"https:\/\/secure.gravatar.com\/avatar\/6f62aa1d55dc8a8289dd18faa628d22e5c34f8d569432403cd0bee21b4875095?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/6f62aa1d55dc8a8289dd18faa628d22e5c34f8d569432403cd0bee21b4875095?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/6f62aa1d55dc8a8289dd18faa628d22e5c34f8d569432403cd0bee21b4875095?s=96&d=mm&r=g","caption":"Lies Vanneste"}}]}},"_links":{"self":[{"href":"https:\/\/www.sequanamedical.com\/nl\/wp-json\/wp\/v2\/posts\/12794","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.sequanamedical.com\/nl\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.sequanamedical.com\/nl\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.sequanamedical.com\/nl\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.sequanamedical.com\/nl\/wp-json\/wp\/v2\/comments?post=12794"}],"version-history":[{"count":0,"href":"https:\/\/www.sequanamedical.com\/nl\/wp-json\/wp\/v2\/posts\/12794\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.sequanamedical.com\/nl\/wp-json\/wp\/v2\/media?parent=12794"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.sequanamedical.com\/nl\/wp-json\/wp\/v2\/categories?post=12794"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.sequanamedical.com\/nl\/wp-json\/wp\/v2\/tags?post=12794"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}